Abstract
Sjögren’s syndrome is an autoimmune disease that primarily affects exocrine glands. Renal involvement of Sjögren’s syndrome may lead to tubulointerstitial disease, whereas secondary glomerulopathies such as anti-neutrophil cytoplasmic antibody (ANCA)-related pauci-immune crescentic glomerulonephritis are rarely observed. In addition, crescent glomerulonephritis that is simultaneously positive for both myeloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-ANCA has never been reported in Sjögren’s syndrome. Here, we report a case of pauci-immune crescentic glomerulonephritis exhibiting positivity for both MPO- and PR3-ANCAs in a patient with primary Sjögren’s syndrome. A 71-year-old female was hospitalized for cough, blood-tinged sputum, and dyspnea two weeks after diagnosis with Sjögren’s syndrome. On admission, serum anti-nuclear antibody, anti-Ro/SS-A antibody, MPO-ANCA, and PR3-ANCA were all positive, and serum blood urea nitrogen and creatinine (Cr) levels were 42.7 and 2.9 mg/dL, respectively. On the seventh day of hospitalization, the patient’s serum Cr level was 5.7 mg/dL, indicating rapidly progressive glomerulonephritis. Renal biopsy resulted in the diagnosis of ANCA-related pauci-immune crescentic glomerulonephritis, for which intravenous methylprednisolone (7 mg/kg/day) was administered for three consecutive days, followed by combination therapy with oral prednisolone (1 mg/kg/day) and intravenous cyclophosphamide (500 mg/m2). The patient was positive in the Schirmer’s I test, and a salivary gland biopsy showed sialadenitis with lympho-plasmacytic infiltrations. On day 28 of hospitalization, the patient was discharged after amelioration of respiratory symptoms and azotemia. At 6 months after discharge, the patient continued to receive appropriate daily medications and was negative for both MPO- and PR3-ANCAs, with a slight elevation in serum Cr levels.
Similar content being viewed by others
References
Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331
Bossini N, Savoldi S, Franceschini F et al (2001) Clinical and morphologic features of kidney involvement in primary Sjögren’s syndrome. Nephrol Dial Transplant 16:2328–2336
Ren H, Wang WM, Chen XN et al (2008) Renal involvement and followup of 130 patients with primary Sjögren’s syndrome. J Rheumatol 35:278–284
Cortez MS, Sturgill BC, Bolton WK (1995) Membranoproliferative glomerulonephritis with primary Sjögren’s syndrome. Am J Kidney Dis 25:632–636
Bosch X, Guilabert A, Font J (2006) Antineutrophil cytoplasmic antibodies. Lancet 368:404–418
Shavit L, Grenader T (2014) Clinical manifestations and outcome of ANCA-related pauci-immune glomerulonephritis in patients with Sjögren’s syndrome. Clin Exp Rheumatol 32(3 Suppl 82):S19–S25
Davies DJ, Moran JE, Niall JF, Ryan GB (1982) Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 285:606
Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558
Evans R, Zdebik A, Ciurtin C, Walsh SB (2015) Renal involvement in primary Sjögren’s syndrome. Rheumatology (Oxford) 54:1541–1548
Böttinger EP, Niles JL, Collins AB, McCluskey RT, Arnaout MA (1992) Antineutrophil cytoplasmic autoantibody-associated vasculitis presenting as Sjögren’s syndrome. Arthritis Rheum 35:1373–1376
Hernández JL, Rodorigo E, De Francisco AL, Val F, González-Macías J, Riancho JA (1996) ANCA-associated pauci-immune crescentic glomerulonephritis complicating Sjögren’s syndrome. Nephrol Dial Transplant 11:2313–2315
Kamachi M, Migita K, Tominaga M et al (1999) Sjögren’s syndrome complicated by MPO-ANCA positive crescentic glomerulonephritis. Nephrol Dial Transplant 14:1033–1034
Tatsumi H, Tateno S, Hiki Y, Kobayashi Y (2000) Crescentic glomerulonephritis and primary Sjögren’s syndrome. Nephron 86:505–506
Kitaura K, Miyagwa T, Asano K et al (2006) Mixed connective tissue disease associated with MPO-ANCA-positive polyangiitis. Intern Med 45:1177–1182
Guillot X, Solau-Gervais E, Coulon A, Debiais F (2009) Sjögren’s syndrome with ANCA-associated crescentic extramembranous glomerulonephritis. Jt Bone Spine 76:188–189
Wang WJ, Wu HS, Chu TS (2011) Anti-neutrtophil cytoplasmic antibody-associated Pauci-immune crescentic glomerulonephritis complicating Sjögren’s syndrome. J Formos Med Assoc 110:473–477
Guellec D, Cornec-Le Gall E, Groh M et al (2015) ANCA-associated vasculitis in patients with primary Sjögren’s syndrome: detailed analysis of 7 new cases and systemic literature review. Autoimmun Rev 14:742–750
Font J, Ramos-Casals M, Cervera R et al (1998) Antineutrophil cytoplasmic antibodies in primary Sjögren’s syndrome: prevalence and clinical significance. Br J Rheumatol 37:1287–1291
Nishiya K, Chikazawa H, Hashimoto K, Miyawaki S (1999) Antineutrophil cytoplasmic antibody in patients with Sjögren’s syndrome. Clin Rheumatol 18:268–271
Ramos-Casals M, Nardi N, Brito-Zerón P et al (2006) Atypical autoantibodies in patients with primary Sjögren’s syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35:312–321
Karagyris G, Stamatopoulos K, Kittas C, Loukopoulous D, Vaiopoulos G (2000) Sjögren’s syndrome co-existing with limited Wegener’s granulomatosis. Rheumatology (Oxford) 39:805–806
Yazisiz V, Ozbudak IH, Nizam I et al (2010) A case of Sjögren’s syndrome with pulmonary-limited Wegener’s granulomatosis. Rheumatol Int 30:1235–1238
Murakami M, Shimane K, Takahashi H, Tomiyama J, Nagashima M (2013) ANCA-associated vasculitis with dual ANCA positivity in coexistence with mixed connective tissue disease. Mod Rheumatol 23:155–161
Guardiola JM, Rodríguez-Pla A, López-Contreras J et al (2000) Simultaneous presence of C-ANCA and P-ANCA in a patient with concurrent Churg-Strauss syndrome and giant cell temporal arteritis. Scand J Rheumatol 29:68–69
Talarico R, Baldini C, Della Rossa A et al (2012) Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clin Exp Rheumatol 30(1 Suppl 70):S130–S138
Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232
Meijer JM, Meiners PM, Vissink A et al (2010) Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960–968
KDIGO Clinical Practice Guidelines for Glomerulonephritis (2011) Chapter 13: pauci-immune focal and segmental necrotizing glomerulonephritis. Kidney Int Suppl 2:233–239
Stegeman CA (2005) Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis: is the glass half full or half empty? J Rheumatol 32:2075–2077
Aggarwal A, Sharma A, Rathi M, Sharma K, Minz RW (2015) Antineutrophil cytoplasmic antibodies (ANCA): role in disease pathogenesis, diagnosis, and monitoring ANCA associated vasculitis. Indian J Rheumatol 10:S48–S53
Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA (2012) Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis–a meta-analysis. Rheumatology (Oxford) 51:100–109
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
In Hee Lee, Seong-Kyu Kim, and Min-Kyung Kim declares that they have no conflict of interests.
Informed consent
This study was approved by the IRB (CR-16-018-L). Written informed consent was not required from the patient for publication of this case report. A copy of the IRB exemption is available for review by the editor of this journal.
Rights and permissions
About this article
Cite this article
Lee, I.H., Kim, SK. & Kim, MK. Dual anti-neutrophil cytoplasmic antibody-related pauci-immune crescentic glomerulonephritis in a patient with Sjögren’s syndrome. Rheumatol Int 36, 1327–1334 (2016). https://doi.org/10.1007/s00296-016-3520-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-016-3520-5